Introduction
Acute promyelocytic leukaemia (APL) is phenotypically characterized by the accumulation in the bone marrow of haemopoietic precursors blocked at the dierentiation stage of promyelocytes (Warrell et al., 1993; Grignani et al., 1994) . APL has two features that distinguish it from other leukaemias: the 15;17 chromosome translocation and the high sensitivity to the dierentiative action of retinoic acid (RA). The t(15;17) interrupts the RARa locus, which encodes a nuclear receptor involved in the regulation of terminal dierentiation in myeloid cells, and the PML locus, which encodes a nuclear protein with negative eects on growth regulation (Chambon, 1996; Liu et al., 1995; Mu et al., 1994; Fagioli et al., 1998; Wang et al., 1998) . The translocation generates a fusion gene that encodes for the PML/RARa fusion protein (Warrell et al., 1993; Grignani et al., 1994) . RA induces dierentiation of promyelocytic blasts both in vitro and in vivo and treatment of APL patients with RA, especially when associated with chemotherapy, induces long-term disease remission in most patients (Warrell et al., 1993; Grignani et al., 1994) . This is the ®rst example of dierentiative therapy of a neoplasm.
There is much evidence to suggest that PML/RARa is connected with both the pathogenesis of the disease and the response of APL blasts to the dierentiative action of RA. Clinically, there is a strict correlation between PML/RARa expression, the promyelocytic phenotype and sensitivity to RA (Warrell et al., 1993; Grignani et al., 1994) . Experimentally, PML/RARa transgenic mice manifest myeloid dierentiative alterations and, in a variable percentage, a promyelocytic leukaemia that is highly sensitive to the dierentiative action of RA both in vitro and in vivo (Brown et al., 1997; Grisolano et al., 1997; Li-Zhen et al., 1997; He et al., 1998) .
The biological and molecular mechanisms that underlie the leukaemogenetic action of PML/RARa are partially understood. The ectopic expression of PML/RARa into haemopoietic precursor cell lines induces block of dierentiation triggered by physiological stimuli, and prolongs survival (Grignani et al., 1993; Rogaia et al., 1995) . In vivo, this may cause accumulation of haemopoietic precursors that are unable to respond to dierentiative physiological stimuli.
It has been proposed that PML/RARa exerted a dominant negative action on the function of the corresponding wild-type PML and RARa proteins (Dyck et al., 1994; Weis et al., 1994; Koken et al., 1994) . This hypothesis was based on transactivation experiments, showing a dominant negative activity of PML/RARa on RARa (Kakizuka et al., 1991; De TheÂ et al., 1991; Pandol® et al., 1991; Kastner et al., 1992) , and on the nuclear localization pattern of these proteins. RARa is nuclear diuse (Gaub et al., 1989) , PML is localized within speci®c subnuclear structures called PML nuclear bodies, while PML/RARa has distinct distribution pattern (microspeckled localization) (Dyck et al., 1994; Weis et al., 1994; Koken et al., 1994; Flenghi et al., 1995) . Expression of PML/RARa produces delocalization within microspeckles of PML and RXR, an RARa cofactor (Chambon, 1996) , and so might alter the function of both PML and RARa. However, based on the demonstration in PML/RARa mutants that neither the delocalization of PML nor of RXR is critical for the action of PML/RARa, it has been proposed that PML/RARa functions as a dominant oncogene that exerts its action directly within microspeckles (Grignani et al., 1996) . Accordingly, PML/RARa is able to form large macromolecular complexes within the nucleus (Nervi et al., 1992) . In addition, the PML and RARa components of the fusion protein interact actively. By expressing the same PML/RARa mutants used in this paper into U937 cells we have shown that integrity of both the PML protein dimerization and RARa DNA binding domains is crucial for the dierentiation block induced by PML/ RARa, and that these domains exert their functions only within the context of the fusion protein (Grignani et al., 1996) .
Likewise, to explain the sensitivity of promyelocytic blasts to the action of RA, it has been hypothesized that the principal eect of RA is to release the dominant negative eect of PML/RARa on wild-type PML or RXR, thereby removing the inhibitory activity on dierentiation of the fusion protein (Dyck et al., 1994; Weis et al., 1994; Koken et al., 1994) . This hypothesis is supported by the fact that RA treatment of APL blasts induces PML/RARa protein degradation, the progressive disappearance of the PML/RARa microspeckles, the reorganization of PML-NBs with restoration of the physiological localization of PML and RXR (Yoshida et al., 1996; Raelson et al., 1996; Nervi et al., 1998) . However, the degradation of PML/ RARa in RA-treated APL cells takes about 24 h, suggesting that the commitment to the dierentiation process occurs in the presence of PML/RARa expression and that the fusion protein might exert a direct eect on the RA-signalling pathway in the presence of RA (Casini and Pelicci, 1998) . Direct evidence for this hypothesis came from: (1) the demonstration that inhibition of PML/RARa degradation does not prevent RA-induced dierentiation ; (2) the identi®cation of RAresistant APL mutant cell clones with constitutive degradation of PML/RARa ; and (3) the demonstration that ectopic expression of PML/ RARa in cells that are poorly sensitive or resistant to RA restores RA-sensitivity (Grignani et al., 1993; Ruthardt et al., 1997) . Notably, PML/RARa enhanced RA-response in U937 cells is also associated with the degradation of the fusion protein . We and others have demonstrated that PML/ RARa is tightly complexed with members of the nuclear corepressor family (N-Cor and SMRT) and that RA induces the dissociation of this complex and triggers the transcriptional activation properties of PML/RARa on RA-target genes Lin et al., 1998; He et al., 1998) . In the case of PLZF/RARa, another RARa-fusion protein expressed in a minority of APLs, the NCoR-PML/RARa complex is not dissociated by RA and the transcriptional repressive function of the fusion protein results unmodi®ed Lin et al., 1998; He et al., 1998) . Notably, PLZF/RARa-expressing APLs are resistant to the dierentiative activity of RA (Warrell et al., 1993; Grignani et al., 1994 ). It appears, therefore, that PML/RARa, is able to directly mediate the dierentiative response to RA. However, the molecular pathways responsible for the RA-response mediated by PML/RARa must still be identi®ed. In particular, it has to be established whether PML/RARa exerts its activity on RA dierentiation in virtue of the RARa sequences that incorporates and whether the PML sequences play any role. We have attempted to resolve this problem by analysing the ability of diverse PML/RARa mutants to enhance RA-response in the U937 monocytic cell line.
Results
Experimental approach and protein stability of the PML/RARa mutants U937 cells dierentiate poorly in response to RA, as determined by the low percentage (about 30 ± 40%) of cells which acquire the capacity to reduce nitroblue tetrazolium (NBT) (Grignani et al., 1993) . A series of PML/RARa mutants (Figures 2 ± 4 and 6) were expressed in the U937 cells using zinc (Zn)-inducible mouse metallothionine (MT) promoter and appropriate cell clones were selected on the basis of two criteria: (1) Zn-induced protein expression comparable to that of PML/RARa in the control U937-PML/RARa expressing clone (PR9 clone); (2) capacity of each clone to undergo RA-induced dierentiation in the absence of Zn induction at a level comparable to that of the parental U937 cells. The majority of the PML/RARa mutants and corresponding U937 cell clones used in this study have been described elsewhere (Grignani et al., 1996) . Each mutant was tested in experiments of PML and PML/RARa coimmunoprecipitation or transactivation of RA-target genes to ensure that the various mutations had only interfered with the desired function (Grignani et al., 1996) .
The stability of the PML/RARa fusion protein is tightly regulated in vivo, both in basal conditions and upon RA-treatment. In the presence of RA, PML/ RARa is degraded within the ®rst 24 h of treatment, through mechanisms that involve activation of the proteasome and members of the caspase protease family (Yoshida et al., 1996; Raelson et al., 1996; Nervi et al., 1998) . To exclude that the eects on RAmediated dierentiation were the consequence of alterations of the half-life of the various PML/RARa mutants, we ®rst analysed the in vivo stability of these proteins. Cells were cultured in the presence or absence of RA and analysed for fusion protein expression by Western blotting after 12 or 24 h. Levels of PML/RARa expression remained unchanged in the absence of RA-treatment, while underwent a marked down-regulation in the presence of RA, which was evident after 12 h of treatment and complete after 24 h (Figure 1) . A comparable kinetic of protein down-regulation was observed in U937 cells expressing the DC/R, DH/R or CC-RAR mutants ( Figure 1 ). It, therefore, appears that the various mutations had no major eects on the stability of the corresponding mutant proteins.
Deletions of the coiled-coil and the RARa zinc-®nger domains abrogate the biological activity of PML/RARa
To establish which portions of the PML/RARa protein are responsible for the increased RAresponse, we investigated the ability of RA to induce myeloid dierentiation in dierent U937 clones with conditional expression of fusion protein mutants carrying deletions of relevant PML or RARa domains. The PML aminoterminal portion retained in PML/RARa contains a Zn-binding domain termed RING, two newly de®ned cysteine/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil (CC) region (Fagioli et al., 1992) . The function of the RING and the B-box regions is unknown, while the CC domain is a dimerization interface through which PML/RARa forms homodimers and heterodimers with PML (Perez et al., 1993) . PML/RARa retains the RARa DNA and RA binding regions and the RXRs dimerization interface and, therefore, the ability to transactivate RA-target genes and to bind RXRs and RA (Kakizuka et al., 1991; De TheÂ et al., 1991; Pandol® et al., 1991; Kastner et al., 1992) . In a ®rst functional screening, we analysed U937 clones expressing PML/RARa mutants with deletions of the PML RING+B1-B2 region (DC/R), the CC region (DH/R) or the RARa zinc ®nger region (P/DR) ( Figure 2a ). Zn-induction of DC/R mutant protein expression, as described for PML/RARa increased the dierentiative response of U937 to RA. In contrast, in cells expressing DH/R or P/DR mutants, RA response was similar to that of parental cells ( Figure 2b ). These results parallel the RA-dependent transactivating ability of the mutants since the DC/R protein displayed the same transactivation potential of PML/ RARa on a RA-responsive element, whereas the DH/ R and the P/DR proteins showed, respectively, an activity similar to RARa or no activity ( Figure 3 ). These ®ndings indicate that the integrity of the PML coiled coil region (deleted in the DH/R mutant) and the RARa DNA-binding domain (deleted in the P/DR mutant) are an absolute requirement for PML/RARa activity on RA-induced dierentiation, and suggest that the functions of these regions (i.e. formation of protein-complexes and regulation of RA-target genes) are critical for the activity of PML/RARa on the RAsignalling pathway. Fusion of PML and RARa sequences is required for the PML/RARa activity on RA-dierentiation To investigate the independent contribution of the PML and RARa components of the fusion protein, we analysed U937 clones that overexpress wild-type PML or RARa or that express PML or RARa mutants carrying the same structural alterations that occur during the t(15;17): a PML mutant with deletion of the carboxyterminal region (PML-PR) or a RARa mutant with deletion of the A region (RARaA 7 ) (Grignani et al., 1996 and Figure 4a) . In all these clones, the RAinduced dierentiative response was similar to that of the parental U937 cells (Figure 4b ), indicating that overexpression of isolated PML or RARa sequences is not sucient to mediate the PML/RARa eect on RAdierentiation. Notably, RARa sequences were expressed at even higher levels than PML/RARa, as shown by Western blottings using anti-RARa antibodies (not shown; see also Grignani et al., 1996) . We then tested whether concomitant expression of altered PML (PML-PR) and RARa (RARaA 7 ) sequences could mimic the eects of PML/RARa. Phenotypic analysis of two U937 clones that coexpress PML-PR and RARa-A 7 mutant proteins from an internal ribosomal entry site (IRES)-based expression vector ( Figure 4a and Grignani et al., 1996) demonstrated that the co-expression of the two mutant proteins had no eect on RA-induced dierentiation (Figure 4b ). Taken together these results indicate that the fusion of PML and RARa sequences is indispensable for the eect of PML/RARa on RA-induced dierentiation, as previously shown for PML/RARa mediated block of vitamin D3 and TGF-b induced dierentiation (Grignani et al., 1996) .
The N-or C-terminal fusion of the PML coiled-coil region to RARa sequences is sucient to mediate RA-response
The results described in the previous sections suggest that the PML coiled-coil domain is sucient to endow RARa with the capacity to increase RA-induced dierentiation. To directly test this hypothesis we engineered two fusion protein mutants where the PML coiled-coil region was fused to RARaA 7 , at either its aminoterminal (CC-RAR) or carboxyterminal (RAR-CC) portion (Figure 5a ). The two mutants were then expressed into U937 cells using expression vectors with the Zn-inducible MT-promoter and several clones were isolated. Two clones for each mutant (RAR-CC#3 and RAR-CC#10; CC-RAR#6 and CC-RAR#9) were selected according to levels of mutant protein expression (Figure 5e ). The functional integrity of the PML coiled-coil portion and of the RARa sequences were evaluated by testing the capacity of each mutant to dimerize with PML or PML/RARa and to act as an RA-inducible transcription factor in coimmunoprecipitation and transactivation experiments, respectively. In PML/RARa-PML coimmunoprecipitation experiments, HeLa cells were transiently co-transfected with expression vectors for the wild-type PML isoform 3 (PML3) (Fagioli et al., 1992) and each of the two PML/RARa mutants. Cell lysates were immunoprecipitated with an antiserum (anti-PML3) speci®c for a PML3 epitope not retained within PML/RARa and blotted with the RPa(F) anti-RARa antiserum (Figure 5c ). Dimerization with PML/RARa was tested in similar coimmunoprecipitation experiments, using a haemoagglutinin (HA) epitope-tagged PML/RARa cDNA and the two PML/RARa mutants. Anti-HA immunoprecipitates were analysed with the anti-RARa antiserum ( Figure  5d ). Transactivation experiments were performed by cotransfecting HeLa cells with the TRE-TK CAT RAresponsive reporter gene and expression vectors for the CC-RAR and RAR-CC mutants in the presence of 10 76 M RA (Figure 3) . The results revealed that both mutants retained the capacity to form soluble complexes with PML and PML/RARa and to transactivate RAreporter genes in vitro to levels similar to PML/RARa. Moreover, all the four analysed U937 clones (RAR-CC#3 and RAR-CC#10; CC-RAR#6 and CC-RAR#9) revealed a RA-dierentiative response comparable to that of PML/RARa U937 (Figure 5b) . Thus, the fusion of the PML coiled-coil region to RARa sequences is sucient to mediate RA-response. Notably, expression of these mutants in U937 cells was also able to block dierentiation induced by other stimuli such as vitamin D3 and TGF-b (not shown).
The capacity of the various PML/RARa mutants to increase RA-dierentiation correlates with their ability to form high molecular weight complexes in vivo
We have previously demonstrated that PML/RARa forms high molecular weight complexes in vivo (7) of Zn PML/RARa complexes mediate retinoic acid response F Grignani et al (Nervi et al., 1992) . As the capacity of PML/RARa to increase the RA response depends on a proteinprotein interaction interface, the PML coiled-coil region, experiments were performed to test the capacity of the various PML/RARa mutants to form high molecular weight complexes in vivo. Nuclear extracts were prepared from COS-1 cells transiently transfected with expression vectors encoding for RARa, PML/RARa, DC/R, DH/R and CC-RAR (not shown) as well as from U937 cells overexpressing RARa, PML/RARa, DC/R, DH/ R, P/DR and CC-RAR (Figure 6 ). Western blot analysis of cellular lysates from U937 cell clones revealed that the various mutants were expressed at comparable levels ( Figure 6, upper panel) . The extracts were labelled with 10 nM [ 3 ]-RA in the absence or in the presence of 200-fold M excess of unlabelled RA, and RA binding analysed by HPLC using a size exclusion column. The elution pro®le of nuclear extracts prepared from U937 cells expressing PML/RARa displayed, as already reported (Nervi et al., 1992) , two major peaks with speci®c RAbinding activity, which eluted with retention times of 42 and 31 min and corresponded to molecular weights of about 50 and 670 kDa ( Figure 5 ). The 50 kDa peak, also present in Zn-untreated U937 cells, represents the endogenous RAR, while the peak in the high molecular fractions represents the PML/RARa macromolecular complexes (Nervi et al., 1992) . However, the morphology of the elution pro®le of nuclear extracts from U937 cells expressing the various PML/RARa mutants diered. A high molecular weight peak characteristic of PML/ RARa was present in the pro®le of the DC/R, P/ DR and CC-RAR mutants, but not in that of the DH/R (Figure 6 ). Similar binding pro®les were obtained in nuclear extracts prepared from COS-1 cell transiently transfected with expression vectors encoding for these mutants (not shown). To summarize, the presence of the PML coiled-coil region within the various fusion protein mutants correlated with their capacities to form high molecular weight complexes in vivo and to increase the dierentiative response to RA, but this correlation does not hold for the P/DR mutant that is unable to bind DNA at RAR responsive elements. Overall the data suggest that protein/ protein complexes mediated by the PML coiled-coil region are responsible for the PML/RARa activity on the RA-signalling pathway. ) immunoprecipitates were blotted (WB) with a-RARa. Expression of the transfected proteins was evaluated by Western blotting of cell lysates with a-RARa (input). (e) Inducible expression of RAR-CC and CC-RAR mutants in U937 cells. Two dierent cell clones of U937 cells stably transfected with the RARa-CC (clones 3 and 10) or the CC-RARa (clones 6 and 9) Zn-inducible expression vectors were cultured for 12 h in the absence (7) or presence (+) of 100 mM ZnSO 4 , lysed and analysed by Western blotting using the anti RARa-F antiserum. PR: control PML/RARa expressing cells
Formation of PML/RARa-PML homodimers is critical for the increased RA-response by PML/RARa
The nature of the high molecular weight complexes that PML/RARa forms in vivo is not known: they may represent complexes of PML/RARa with itself and/or with other nuclear proteins, including wild-type PML. In fact, the PML coiled-coil region has been demonstrated to be crucial for the formation of both PML/RARa homodimers and PML/RARa-PML heterodimers (Perez et al., 1993) . The PML coiledcoil region consists of four clusters of hydrophobic aminoacids heptad repeats (H1, H2, H3 and H4) and we have recently demonstrated that deletion of H2 (DH2/R mutant, Figure 7a ) abrogates formation of PML/RARa-PML heterodimers, but not PML/RARa homodimers, whereas deletion of H1 (DH1/R, Figure  7a ) has no eect on either (Grignani et al., 1996) . Moreover, deletion of the aminoterminal portion of the fusion protein, including H1 (PDCD1/R mutant, Figure  7a ), abrogates both homodimer and heterodimer formation (Grignani et al., 1996) . For this reason we investigated the dierentiative response to RA of U937 clones that overexpress PML/RARa mutants with H1 (DH1/R and PDCD1/R) or H2 (DH2/R) deletions. RA response was found to be enhanced in both DH1/R and DH2/R expressing clones (Figure 7b ) and unchanged in PDCD1/R clones, suggesting that the formation of PML/RARa homodimers, but not of PML/RARa-PML heterodimers, is crucial for enhanced RA response. Again the biological properties of the mutants correlate with their RA-dependent transactivating potential.
Discussion
Expression of PML/RARa into dierent haematopoietic cell lines revealed that the fusion protein is capable of mediating the dierentiative response to RA (Grignani et al., 1993; Ruthardt et al., 1997) . Here, we investigated the molecular mechanisms underlying the biological activity of the fusion protein on RAsignalling. As model system, we have chosen the U937 cell line, whose RA-sensitivity is markedly increased by PML/RARa expression (Grignani et al., 1993) . We 76 M RA for 5 days, in the presence (+) or absence (7) or Zn expressed in U937 cells PML/RARa mutant proteins deleted in relevant functional regions and studied their biological eects. Similarly to the PML/RARa protein, the mutants are degraded in response to RA treatment of the cells. The degradation kinetic is similar to that of the PML/RARa protein and therefore does not account for the dierent biological eects of the proteins. Notably, biologically inactive proteins are also degraded, indicating that activation of speci®c proteolysis by RA is a function of the integrity of RARa.
First, we showed that the enhanced RA-differentiative response of PML/RARa-expressing cells, similarly to the block of vitamin D3 and TGF-b induced dierentiation (Grignani et al., 1996) is not merely the consequence of overexpression of the RARa component of the fusion protein. Overexpression of wild-type RARa or of an aminoterminally truncated RARa mutant as in the fusion protein, does not signi®cantly increase the sensitivity of U937 cells to RA. This implies that the available level of RARa protein is not a limiting factor in determining the response to RA in U937 cells. Indeed, overexpression of RXR in the U937 cells overexpressing RARa increased sensitivity to RA to the same extent as PML/RARa (unpublished observation). It, therefore, seems that the RA-response of U937 cells depends on the availability of the RAR-RXR heterodimers and that RXR is dose limiting. The fact that PML/RARa alone is able to mediate RA response suggests that other mechanisms or molecules co-operate with it in mediating RA-response.
Second, we showed that the RARa zinc-®nger DNA-binding region is required for the biological function of PML/RARa. The involvement of this region has direct functional implication, e.g. that binding of PML/RARa to RA-responsive elements and transactivation of RA-target genes is crucial for its activity on the RA-signaling pathway. This agrees with recent ®ndings showing that pharmacological concentrations of RA cause the release of the corepressorhistone deacetylase complex from PML/RARa Lin et al., 1998; He et al., 1998) . Likewise, RA treatment of U937 cells induces, in the presence of PML/RARa expression, a dramatic increase in the activation of certain RA-target genes, for example transglutaminase type II and RARb (Ruthardt et al., 1997) . Notably, the biological eects of the mutants are in agreement with their RAdependent transcription factor action, since biologically active mutants have a transactivating activity similar to that of PML/RARa and increased with respect of that of RAR. Taken together, these results reinforce the hypothesis that high RA concentrations trigger the transactivating potential of PML/RARa on RA-target genes and release the dominant negative eect exerted by the fusion protein on the endogenous RA-signalling pathway at low RA concentrations (Pandol® et al., 1991; Dyck et al., 1994; Weis et al., 1994; Koken et al., 1994) .
Our study also demonstrates that the PML coiledcoil region is essential for the biological activity of PML/RARa and that it is the only portion of PML that is both necessary and sucient. Deletion of the PML coiled-coil region abrogates the eects of the fusion protein on RA-induced dierentiation, while its fusion to either the C-or the N-terminal region of RARa confers upon the RARa sequences the capacity to increase the RA response. Since the PML coiled-coil region is a dimerization interface, complex formation by PML/RARa is essential to increase RA-response. We demonstrated that PML/RARa forms high molecular weight complexes in vivo (Nervi et al., 1992) and that the coiled-coil region is responsible for the formation of these complexes. Furthermore, only PML/RARa mutants that form high molecular weight complexes are able to mediate an increased RAresponse.
The nature of the high molecular weight complexes that PML/RARa forms in vivo is not known. It could be that PML/RARa homodimers and PML/RARa-PML heterodimers take part in these complexes, since stability of both depends on the integrity of the PML coiled-coil region (Perez et al., 1993) . However, the analysis of PML/RARa mutants with dierent homodimers and heterodimers forming capacities demonstrated that the PML/RARa homodimers could generate the molecular complex that mediates the RA response, whereas PML/RARa-PML heterodimerizations is not crucial. Therefore, in U937 cells, high levels of PML/RARa homodimers could be functionally equivalent to high levels of the RARa-RXR heterodimer. Notably, PML/RARa homodimers have been shown to bind RA-target sequences with the same or higher anity than RAR/RXR homodimers (Perez et al., 1993) .
An alternative possibility is that the molecular species responsible for the enhanced RA-response are heterodimers of PML/RARa with as yet unidenti®ed PML-interacting protein(s) are. There is now some evidence that PML is directly involved in the regulation of the RA response (Wang et al., 1998) . Therefore, it might be that PML or putative PMLassociated proteins are directly implicated in the transcriptional regulation of RA-target promoters. However, PML has been shown to be involved in the regulation of several other promoters in vivo, both of cellular (steroid hormone receptor-target promoters) and viral (CMV promoter, LTR) (Mu et al., 1994) origin. Thus, PML or PMLassociated proteins could in¯uence transcription in general, and increase RA-induced transcriptional activation when fused to RARa or complexed with PML/RARa. Identi®cation of PML-associated proteins and characterization of the PML/RARa high molecular weight nuclear complexes should give a greater insight into these issues.
Materials and methods

PML/RARa mutants and expression vectors
For the CC-RAR construction, the PML coiled coil region and RARaA 7 (Grignani et al., 1996) were PCR ampli®ed with the oligonucleotides 5'-TGTGGACGCGCGGTAACCA-3', 5'-TTG CAG GCT CTT GGATAT C CTCCT GGCGC AG-3', and 5'-AGGCAGATATCGAGACCCAGA-3', 5'-AGCCT-GAGGACTTGTCCTGAC-3' respectively, and an EcorV site (underlined) was introduced 3' to the last heptad cluster and 5' to the RARa
7
. Similarly in RAR-CC a XhoI site (underlined) was generated by PCR (oligonucleotides 5'-AG-ACCGCCAGGACCTGGAGC-3', 5'-ACTCCCCTCGAGC-GCCCACGCCACATGGA-3' and 5'-CTTGACAGCAG-CCCTCGAGAGCTCAAGTGCGAC-3', 5'-CTGCGCCAG-GAGGAGCCCCAGTGACTGCAA-3' respectively) at either the RARa aminoterminal or PML coiled-coil region carboxyterminal. The CC-RAR and RAR-CC cDNAs were then subcloned into the pMT Zn-inducible expression vector (Grignani et al., 1993) and in the SV40 based pSG5 expression vector (Stratagene). For the dimerization experiments, a PML3 cDNA (Fagioli et al., 1992) was also subcloned in the pSG5 vector. The HA-tagged PML/RARa cDNA (HAPR) was described elsewhere (Grignani et al., 1996) . All other constructs have been described elsewhere (Grignani et al., 1996) .
Cell culture, transfection and Western blotting U937 cells were maintained in RPMI 1640 medium supplemented with 10% foetal calf serum. Cells were transfected by electroporation, selected in G418 and subcloned under limiting dilution conditions. The RA induced dierentiation was investigated by the NBT assay, as previously described (Grignani et al., 1993) . Expression of the exogenous proteins was evaluated by Western blotting after 6 ± 12 h induction with 100 mM ZnSO 4 using the PGM3 (Flenghi et al., 1995) or anti-RARa-F (gifts from P Chambon, Strasbourg, France) antibodies and revealed with the ECL method (Amersham, Little Chalfont, UK).
Coimmunoprecipitation experiments
In the PML dimerization assay, HeLa cells were transiently transfected with 1 mg of pSG5-based expression vectors for the various PML/RARa mutants and PML3. After 48 h cells were washed in PBS and collected in HEPES 50 mM, NaCl 250 mM, EDTA 5 mM, DTT 1 mM, NP40 0.1%, PMSF (Sigma) 1 mM, leupeptin (Sigma) 1 mg/ml, aprotinin (Sigma) 1 mg/ml (E1A buer). The cell suspension was brie¯y sonicated and the lysates clari®ed by centrifugation. Immunoprecipitation was obtained by adding protein A Sepharose (Pharmacia) and the anti PML-3 antiserum. Sepharose beads were washed in E1A buer and resuspended in SDS sample buer. Immunoprecipitates were Western blotted with the anti-RARa-F antisera by the ECL method. Aliquots of the lysates were tested for PML/RARa or mutant protein expression in the transfected cells by antiRARa Western blotting. In the PML/RARa dimerization assay the vector for the PML3 protein was substituted by the expression vectors for the HA-tagged PML/RARa protein. Cell lysates were immunoprecipitated with an anti-HA monoclonal antibody (Boehringer-Mannheim, Milano, Italy).
Transactivation experiments
Transactivation experiments were carried out as reported (Pandol® et al., 1991) . Brie¯y, HeLa cells were co-transfected with 0.5 mg of the TRE-TK-CAT reported gene, 0.5 mg of expression vectors for RARa, PML/RARa, or its mutants and with 0.5 mg of a b-Gal expression vector for normalization. Eighteen hours after transfection 1 mM RA was added to the cultures. Cells were collected after 24 h of RA treatment. An equal number of b-Gal units were used for CAT assays.
Retinoic acid binding assays and analysis of PML/RARa macromolecular complexes U937 clones overexpressing RARa, PML/RARa or the various PML/RARa mutants or transiently transfected COS-1 cells (pSG5 expression vector) were used for RA binding analysis. Nuclear extracts (1 mg) were incubated for 18 h at 48C, in the presence of 10 nM All-trans-[
3 H]retinoic acid (50.7 Ci/mmol; DuPont/NEN, Boston, MA, USA). Non-speci®c binding activity was measured at each point in the presence of 200-fold molar excess of unlabelled RA (data not shown). [ 3 H]t-RA binding was analysed by highperformance liquid chromatography (HPLC) performed at 48C using a size exclusion column Superose 6 HR 10/30 (Pharmacia, Uppsala, Sweden). The eluent was PTG buer containing 0.4 M KCI and the¯ow rate was 0.4 ml/min. Apparent molecular weights were calculated on the basis of the elution times of a series of marker proteins used to calibrate the system.
